Condition: Crohn Disease (CD) · IBD (Inflammatory Bowel Disease) · IBD - Inflammatory Bowel Disease · Sponsor: University of British Columbia
Children with Crohn's disease (CD), a type of Inflammatory Bowel Disease (IBD), often face serious health challenges, including poor growth, frequent hospital stays, and long-term medication use. Although biologic drugs like infliximab, an anti-TNFα (Tumor necrosis factor α) medication, have improved treatment, they don't work for everyone: many children still experience symptoms or disease flare-ups. Nutritional therapies, especially the Crohn's Disease Exclusion Diet (CDED), may help improve treatment outcomes. This study will assess whether starting CDED at the same time as infliximab leads to better responses to treatment. The goal of this study is to improve how well children respond to therapy, reduce drug exposure, and support better long-term health.
This description comes directly from the study's public registry record.
Kevan Jacobson, MBBCh, FRCP, FRCPC, AGAF, CAGF · 604-875-2332 · kjacobson@cw.bc.ca
Fanny Lemarie, MSc, PhD · 604-441-4992 · fanny.lemarie@ubc.ca
Always discuss trial participation with your own doctor first.
| The University of British Columbia | Vancouver, British Columbia, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07314606